Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1937]

ATRA-ATO regimen with idarubicin could become the new standard of care in high...

Dr Uwe Platzbecker - University Hospital Leipzig, Leipzig, Germany

ATRA-ATO regimen with idarubicin could become the new standard of care in high-risk acute promyelocytic leukaemia ( Dr Uwe Platzbecker - University Hospital Leipzig, Leipzig, Germany )

Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in...

Prof Meletios Dimopoulos - University of Athens, Athens, Greece

Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line ( Prof Meletios Dimopoulos - University of Athens, Athens, Greece )

Ponatinib is better than imatinib for frontline treatment of newly diagnosed...

Prof Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain

Ponatinib is better than imatinib for frontline treatment of newly diagnosed Ph+ acute lymphoblastic leukaemia ( Prof Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )

More effective treatment options required for patients with MM post...

Dr Claudio Cerchione - IRCCS, Meldola, Italy

More effective treatment options required for patients with MM post lenalidomide exposure ( Dr Claudio Cerchione - IRCCS, Meldola, Italy )

Ibrutinib and venetoclax continue to provide benefits for patients with chronic...

Dr Paolo Ghia - Università Vita-Salute San Raffaele, Milan, Italy

Ibrutinib and venetoclax continue to provide benefits for patients with chronic CLL and SLL ( Dr Paolo Ghia - Università Vita-Salute San Raffaele, Milan, Italy )

Lower levels of inflammatory markers and tumour burden is linked to...

Prof Bertrand Arnulf - Hôpital Saint-Louis, Paris, France

Lower levels of inflammatory markers and tumour burden is linked to improvements in PFS with Ide-Cel in R/R multiple myeloma ( Prof Bertrand Arnulf - Hôpital Saint-Louis, Paris, France )

Combination of zanubrutinib and venetoclax shows promise in high-risk TN CLL...

Dr Alessandra Tedeschi - Niguarda Cancer Center, Milan, Italy

Combination of zanubrutinib and venetoclax shows promise in high-risk TN CLL/SLL with del(17p) and/or TP53 mutation ( Dr Alessandra Tedeschi - Niguarda Cancer Center, Milan, Italy )

Isatuximab in combination with pomalidomide and dexamethasone shows promising...

Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece

Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM ( Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece )

Encouraging results using mismatched unrelated donors in stem cell...

Dr Monzr Al Malki and Dr Steven Devine

Encouraging results using mismatched unrelated donors in stem cell transplantation ( Dr Monzr Al Malki and Dr Steven Devine )

Importance of MRD in newly developed multiple myeloma

Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France

Importance of MRD in newly developed multiple myeloma ( Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France )

Teclistamab continues to demonstrate deep and durable responses in relapsed...

Dr Alfred Garfall - Penn Medicine Abramson Cancer Center, Philadelphia, USA

$Teclistamab continues to demonstrate deep and durable responses in relapsed/refractory multiple myeloma ( Dr Alfred Garfall - Penn Medicine Abramson Cancer Center, Philadelphia, USA )$

Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed...

Prof Thierry Facon - Chu De Lille, Lille, France

Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed multiple myeloma ( Prof Thierry Facon - Chu De Lille, Lille, France )

More from ecancer